comparemela.com
Home
Live Updates
Supplemental New Drug Application for Akeso's Cadonilimab (P
Supplemental New Drug Application for Akeso's Cadonilimab (P
Supplemental New Drug Application for Akeso's Cadonilimab (PD-1/CTLA-4) Accepted by NMPA for First-line Treatment of Gastric Cancer
/PRNewswire/ -- Akeso (9926.HK) announced the China National Medical Products Administration (NMPA) has accepted the supplemental new drug application (sNDA)...
Related Keywords
China ,
Lin Shen ,
Guangdong ,
Peking ,
Beijing ,
Hong Kong ,
Ji Jiafu ,
Yu Xia ,
Akeso Inc ,
China National Medical Products Administration ,
University Cancer Hospital ,
Professor Ji Jiafu ,
Peking University Cancer ,
Professor Lin Shen ,
Summit Therapeutics ,
Main Board ,
Stock Exchange ,
Takeso ,
Nc ,